Navigation Links
CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
Date:5/15/2012

WOBURN, Mass., May 15, 2012 /PRNewswire/ -- CutisPharma, Inc. announced the presentation of homogeneity and stability studies for compounded formulations of several "Magic Mouthwash" suspensions using FIRST®- Unit- of- use Prescription Compounding Kits.  The poster presentation, by Anisa Gandhi, was at the April 20th American Association of Pharmaceutical Scientists, Northeast Regional Discussion Group (NERDG) Regional Meeting.

"Magic Mouthwash" is commonly prescribed by physicians nationwide.  The purpose behind magic mouthwash is to combine various ingredients with different advantages depending on the patient's symptoms.  Currently magic mouthwash is extemporaneously prepared or is prepared using FIRST® - Magic Mouthwash Compounding Kits.

The active ingredients used in these FIRST® Magic Mouthwash kits are comparable to those found in the most routinely prescribed "Magic Mouthwash" formulations.  These active ingredients are: diphenhydramine hydrochloride, lidocaine hydrochloride, and modified Maalox® in FIRST® - Mouthwash BLM; diphenhydramine hydrochloride, lidocaine hydrochloride, and nystatin in FIRST®  -BXN Mouthwash; diphenhydramine hydrochloride, hydrocortisone, and nystatin in FIRST®  - Duke's Mouthwash; and diphenhydramine hydrochloride, hydrocortisone, nystatin, and tetracycline in FIRST®  - Mary's Mouthwash.

Ms. Gandhi's presentation demonstrated that FIRST®  -Mouthwash Kits are uniform in nature for active ingredients.  FIRST®  Magic Mouthwash Kits are convenient with reliable stability and uniformity data, whereas, the traditional compounding process generally does not have this data available.

FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction.  Using FIRST® Mouthwash kits, the pharmacist can compound a prescription with accuracy faster than those prepared in the conventional way.  A single NDC number assigned for the entire kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits, and three lansoprazole suspension kits.  Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

"CutisPharma is committed to maintaining the scientific integrity of the products it develops and commercializes.  Studies of this nature also demonstrate the scientific reliability of FIRST® products, as well as confirm their user-friendliness and time-saving benefits" said Dr. Indu Muni, President  & CEO of CutisPharma.

About CutisPharma
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com.


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding
2. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
3. Centrix Pharmaceutical, Inc. Announces Agreement With CutisPharma, Inc. to Promote FIRST® - Progesterone VGS Compounding Kit
4. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
5. CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits
6. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. ADVENTRX Announces 9-Month Stability Data Results for ANX-530
9. Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
10. Stability Testing Course is Taking the Online Training Format by Storm!
11. Ethicon Endo-Surgery Introduces First Powered Endocutter with Enhanced System-Wide Compression and Stability, Allowing Surgeons Greater Control in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD ... ultimately, a cure. , The grants are awarded through a competitive application process ... a wide array of backgrounds and expertise in all areas relevant to PD research. ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... ... pain afflicting 8 of 10 Americans at some point in their lives, some of us ... equally vexing condition stems from a variety of causes that can be effectively targeted by ... president of Atlantic Spine Center. , Nestled between your neck and lower back, the ...
Breaking Medicine News(10 mins):